 The oral presentation, entitled: Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy, given by Dr. Grant Blouse, senior vice president of translational research, provided preclinical results of CB 2679d-GT, the companys novel FIX gene therapy. CB 2679d-GT was designed to achieve clinically relevant FIX levels at a reduced viral load by combining engineered AAV capsids with Catalysts novel high potency FIX transgene. 